Behçet's Disease
New Behçet's disease research, summarized each month in plain language.
2026 so far: So far in 2026 (January 2026 to September 2026), two small placebo-controlled trials reported fewer Behcet mouth ulcers and less pain, while real-world studies refined biologic and targeted options based on which organs were involved. Read the 2026 review
We also cover clinical trials.
Yearly update
2026 so far
- Oral-ulcer trial results. Controlled trial evidence emerged for ulcer reduction over 12 weeks.
- Treatments by organ. Evidence clustered by organ: uveitis, gut disease, and refractory cases.
- Anti-TNF for vessels. Pooled and real-world data supported vascular response, with safety reporting uneven.
- Practical medication use. Real-world studies tested formulation changes and add-ons for mucocutaneous control.
- Monitoring by organ. Monitoring shifted toward organ-targeted tests and imaging consensus.
New
September 2026
- Low-dose IL-2 trial. A small controlled trial found fewer mouth ulcers and less pain.
- Upadacitinib case reports. Small reports linked it to better control in refractory disease.
- Blood marker tracking. One blood protein index matched activity; GDF-15 did not.
August 2026
- Ulcer symptom control. Adding paeony extract to colchicine meant fewer early ulcer flare-ups, but diarrhea increased.
- Key eye scans. Experts agreed on a short list of eye scans to track uveitis.
- Brain artery MRI. Artery wall changes were seen mainly during Neuro-Behcet attacks.
July 2026
- Eye inflammation. Adalimumab was linked to calmer uveitis and less steroid use.
- Intestinal symptoms. Ustekinumab was linked to symptom improvement in a small study.
- Vessel and heart risks. Artery and heart involvement was linked to higher risk outcomes.
June 2026
- Eye inflammation control. Two immune medicines showed similar overall uveitis control.
- Uveitis scoring system. An eye-based score separated Behcet uveitis better than usual criteria.
- Similar conditions. Proposed criteria aimed to reduce confusion with related syndromes.
May 2026
- Switching to self-injected infliximab. In observational reports, many people stayed stable after switching from IV infliximab to a self-injected form, although some relapsed and switched back.
- Adalimumab for uveitis dosing changes. In non-infectious uveitis, adalimumab was linked to lower steroid use and better average vision, but relapses were common when doses were spaced farther apart.
- Mouth ulcers and later bowel involvement. In a registry of people who started with only mouth and skin symptoms, major mouth ulcers were most strongly linked to later intestinal involvement.
April 2026
- Eye damage and vision risk. In Behcet’s-related uveitis, damage to the macula or optic nerve was most strongly linked to later permanent vision loss.
- Blood markers and active disease. Higher blood levels of asprosin and granzyme K were reported more often during active Behcet’s disease.
- Interferon-related T-cell pattern. One study found a type I interferon–related CD4 T-cell pattern that was lower in active uveitis and higher after interferon‑alpha therapy.
- Frailty and daily life. Pre-frailty and frailty were common and were linked to lower quality of life.
March 2026
- Immune-targeting drugs. In a few hard-to-treat cases, newer immune-targeting medicines were linked with symptom control after other treatments had not worked.
- Stool test for gut inflammation. In intestinal Behçet’s, fecal calprotectin (a stool inflammation test) matched bowel-scope findings better than CRP (a blood test).
- Aneurysm imaging and procedures. Reports described how scans are used to follow aneurysms and how procedures may be timed around inflammation-focused treatment.
February 2026
- Mouth ulcer relief (12 weeks). In a 12-week placebo-controlled trial, mufemilast was linked with fewer mouth ulcers and less mouth pain than placebo.
- Biologics vary by organ. Across non-TNF biologics, response patterns differed by organ involvement (eye, nervous system, joints, and skin or mouth), so the same drug did not look consistent across symptoms.
- Pregnancy complication risk. A pooled review linked Behcet disease with higher rates of pregnancy complications (including blood clots and miscarriage), and a separate vasculitis cohort linked worse outcomes with relapse during pregnancy.
- CRP indices and vascular disease. In one cohort, CRP-based blood indices separated people with vascular involvement better than several other indices, but they did not predict mortality in that dataset.
January 2026
- Vessel inflammation. Pooled studies linked infliximab to higher response in vascular disease.
- Anti-TNF results. Infliximab and adalimumab showed similar early remission in real-world data.
- Colchicine switch. Switching colchicine forms was linked to better mouth, skin, and joint scores.
- Disease activity markers. Ultrasound scores and a blood-count marker tracked activity in small studies.
Get the monthly update by email
Subscribe here to receive an email when a new monthly Behçet's disease update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).